Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 6/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.50 |
| ▸ | WNT3A | P56704 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.50 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28798675 | 0.84 | PARP1 (0.72) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL7782055 | 0.80 | PARP1 (0.67) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL7783296 | 0.79 | PARP1 (0.65) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL7781500 | 0.79 | PARP1 (0.65) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL7783308 | 0.79 | PARP1 (0.65) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL18711836 | 0.77 | PARP1 (0.62) | PARP1PARP3PARP15CYP1A2HIF1A | |
| SCHEMBL7776883 | 0.76 | PARP1 (0.60) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL7781343 | 0.76 | PARP1 (0.60) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL12735626 | 0.74 | PARP1 (0.59) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL10150407 | 0.74 | PARP1 (0.59) | PARP1PARP3PARP15CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025109076-A1 | BIOMARKERS FOR IDENTIFYING PATIENTS HAVING TUMORS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY | INSTITUT CURIE (FR) | 2025-05-30 | — | — | WO | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | claimed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | claimed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| WO-2010082813-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025227060-A1 | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER | INSILICO MEDICINE IP LIMITED (CN) | 2025-10-30 | — | — | WO | disclosed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | disclosed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010082813-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | disclosed |
| EP-1142881-A1 | POLY(ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | PARP1 2339/4885PARP3 1279/4885PARP15 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.